Want to see ANAB full AI Analyst Report?
Top Page
AnaptysBio
(NASDAQ:ANAB)
Select Model
Select Model
Rating:49Neutral
Price Target:
$56.00
▲(3.42% Upside)
Action:Reiterated
Date:07/16/26
Overall score reflects improving operating and cash-flow trends versus prior years but elevated risk from a weakened TTM balance sheet (sharp equity decline, higher leverage) and volatile, royalty/milestone-driven revenue. Technicals are soft in the near term with the stock below key short-term moving averages, while valuation is constrained by ongoing net losses and no dividend support. Corporate actions (spin-off and leadership additions) are supportive but depend on smooth execution and sustained royalty performance.
Positive Factors
Royalty-focused business model
The April 2026 spin-off structurally repositions AnaptysBio as a royalty-focused, lower-cost franchised company that retained Jemperli/imsidolimab royalties and related collaborations. This durable shift reduces direct R&D burden and increases the proportion of cash flows tied to partner commercialization outcomes, improving long-term cash predictability if partners perform.
Negative Factors
Weakened balance sheet / higher leverage
Trailing results show a meaningful deterioration in capital structure with debt-to-equity above 1x and prior periods of very high leverage. This persistent volatility in balance sheet strength raises refinancing, covenant and liquidity risks, constraining flexibility to manage shocks or opportunistic investments over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Royalty-focused business model
The April 2026 spin-off structurally repositions AnaptysBio as a royalty-focused, lower-cost franchised company that retained Jemperli/imsidolimab royalties and related collaborations. This durable shift reduces direct R&D burden and increases the proportion of cash flows tied to partner commercialization outcomes, improving long-term cash predictability if partners perform.
Read all positive factors
AnaptysBio Key Performance Indicators (KPIs)
AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.58B
Dividend YieldN/A
Average Volume (3M)738.88K
Price to Earnings (P/E)―
Beta (1Y)0.96
Revenue Growth107.73%
EPS Growth82.33%
CountryUS
Employees104
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.85
Shares Outstanding29,608,480
10 Day Avg. Volume927,720
30 Day Avg. Volume738,876
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)24.14
Price to Sales (P/S)3.83
P/FCF Ratio45.80
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$80.67Price Target Upside48.97% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$94.26M
AnaptysBio Business Overview & Revenue Model
Company Description
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States. The company’s products include Rosnilimab, a selective pathogenic T cell deplete...
How the Company Makes Money
AnaptysBio makes money primarily through collaboration and licensing arrangements rather than product sales (it is a clinical-stage company and does not consistently generate revenue from commercialized products). Key revenue streams typically inc...
AnaptysBio Financial Statement Overview
Summary
Income Statement
52
Neutral
Balance Sheet
45
Neutral
Cash Flow
57
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 232.39M | 234.60M | 91.28M | 17.16M | 10.29M | 63.17M |
| Gross Profit | 270.54M | 232.18M | -72.56M | -115.13M | -78.51M | -35.32M |
| EBITDA | 58.49M | 69.25M | -92.74M | -156.42M | -105.26M | -55.71M |
| Net Income | -26.79M | -13.23M | -145.23M | -163.62M | -128.72M | -57.80M |
Balance Sheet | ||||||
| Total Assets | 329.68M | 364.39M | 483.83M | 452.39M | 610.38M | 643.07M |
| Cash, Cash Equivalents and Short-Term Investments | 286.45M | 311.64M | 385.37M | 390.90M | 441.24M | 548.10M |
| Total Debt | 277.36M | 14.11M | 369.46M | 17.81M | 19.45M | 20.95M |
| Total Liabilities | 316.94M | 327.19M | 412.97M | 364.29M | 348.28M | 286.64M |
| Stockholders Equity | 12.75M | 37.21M | 70.87M | 88.10M | 262.10M | 356.43M |
Cash Flow | ||||||
| Free Cash Flow | 4.41M | 19.61M | -135.69M | -121.61M | -73.95M | -47.29M |
| Operating Cash Flow | 4.48M | 19.70M | -135.34M | -120.80M | -73.59M | -45.92M |
| Investing Cash Flow | 248.17M | 228.03M | 95.40M | 144.75M | -394.85M | 38.84M |
| Financing Cash Flow | -102.81M | -132.61M | 127.05M | -59.30M | 44.02M | 252.30M |
AnaptysBio Technical Analysis
Positive
54.15
Price Trends
57.49
Negative
54.79
Positive
42.57
Positive
Market Momentum
-1.74
Positive
47.39
Neutral
65.94
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Positive. The current price of 54.15 is below the 20-day moving average (MA) of 56.97, below the 50-day MA of 57.49, and above the 200-day MA of 42.57, indicating a neutral trend. The MACD of -1.74 indicates Positive momentum. The RSI at 47.39 is Neutral, neither overbought nor oversold. The STOCH value of 65.94 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANAB.
AnaptysBio Risk Analysis
AnaptysBio disclosed 49 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
AnaptysBio Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | $1.09B | -7.97 | 474.91% | ― | 131.13% | 35.61% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $343.97M | -4.49 | -39.75% | ― | -100.00% | -2.72% | |
49 Neutral | $1.58B | -62.78 | 442.91% | ― | 107.73% | 82.33% | |
49 Neutral | $199.30M | -4.13 | -21.91% | ― | -84.55% | -1998.74% | |
48 Neutral | $1.00B | -5.67 | -45.95% | ― | ― | -3.83% |
* Healthcare Sector Average
ANAB
AnaptysBio
55.13
40.11
266.95%
MGTX
Meiragtx Holdings
12.29
4.34
54.59%
KROS
Keros Therapeutics
10.25
-4.16
-28.87%
CMPX
Compass Therapeutics
1.98
-0.93
-31.96%
OLMA
Olema Pharmaceuticals
11.76
6.78
136.14%
AnaptysBio Corporate Events
Business Operations and Strategy
AnaptysBio Subleases San Diego Facility to First Tracks
Neutral
Jun 22, 2026
On June 15, 2026, AnaptysBio entered into a sublease agreement with First Tracks Biotherapeutics to sublease approximately 45,057 rentable square feet of its San Diego premises at 10770 Wateridge Circle for an initial term of 12 months. The arrang...
DividendsRegulatory Filings and Compliance
AnaptysBio Details Tax Treatment of Spin-Off Dividend
Neutral
May 29, 2026
AnaptysBio, Inc. has filed IRS Form 8937 and plans to make the related information available on its website to explain the dividend received by stockholders from the separation and spin-off of First Tracks Biotherapeutics, Inc. The filing outlines...
Business Operations and StrategyRegulatory Filings and Compliance
AnaptysBio Adjusts Fiscal Year-End and Reporting Calendar
Neutral
May 21, 2026
On May 18, 2026, AnaptysBio, Inc.’s board of directors approved a shift in the company’s fiscal year-end from December 31 to June 30, with the next fiscal year set to begin on July 1, 2026. The company will file a transition Form 10-KT...
Executive/Board Changes
AnaptysBio Appoints New CFO and Board Director
Positive
May 11, 2026
On May 11, 2026, AnaptysBio, Inc. appointed Christopher M. Murphy as Chief Financial Officer, formalizing his role through a consulting agreement that designates him as an independent contractor with performance-based compensation and a $1.75 mill...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.